Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial

BACKGROUND: In the phase III AVAGAST trial, the addition of bevacizumab to chemotherapy improved progression-free survival (PFS) but not overall survival (OS) in patients with advanced gastric cancer. We studied the role of Angiopoietin-2 (Ang-2), a key driver of tumour angiogenesis, metastasis and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: Hacker, Ulrich T, Escalona-Espinosa, Laura, Consalvo, Nicola, Goede, Valentin, Schiffmann, Lars, Scherer, Stefan J, Hedge, Priti, Van Cutsem, Eric, Coutelle, Oliver, Büning, Hildegard
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4984795/
https://ncbi.nlm.nih.gov/pubmed/27031850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.30
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares